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Abstract: Neoadjuvant therapy is integral to the treatment of early-stage breast cancer.
Goals of treatment include surgical downstaging of the tumor, rendering inoperable tumors
resectable, and de-escalating axillary surgery in those with clinically positive nodes.
Additionally, response to treatment provides important prognostic information regarding
risk of recurrence and guides future adjuvant treatment. Although chemotherapy serves as
the backbone of neoadjuvant treatment, an increased understanding of the tumor’s clinical
course as well as its molecular and genetic make-up aids in individualizing treatment and
developing novel agents. This review summarizes current clinical approaches and the future
direction to the management of breast cancer patients in the neoadjuvant setting.
Keywords: neoadjuvant chemotherapy, neoadjuvant endocrine therapy, pCR, breastconserving surgery
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Introduction
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancerrelated death in women globally.1 Treatment decisions are tailored based on the size of
breast cancer, degree of lymph node involvement, expression of the estrogen receptor
(ER) and progesterone receptor (PR), and expression of the HER2 protein.
Neoadjuvant therapy refers to the administration of systemic therapy, either chemother
apy or endocrine therapy, prior to definitive breast surgery. Patients who derive clinical
benefit from neoadjuvant chemotherapy (NACT) include patients with high-risk breast
tumors, large breast tumors, and locally advanced tumors, including those initially
ineligible for surgery. The goals of NACT include rendering inoperable tumors resect
able, surgical downstaging for patients who prefer breast conservation, and deescalating axillary surgery in those with clinically positive nodes.

Rationale for Neoadjuvant Systemic Therapy Compared to
Adjuvant Therapy
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Early initiation of systemic therapy was thought to improve overall survival (OS) in
high-risk patients receiving NACT. However, in the Early Breast Cancer Trialists’
Collaborative Group (EBCTCG) meta-analysis, no difference was observed in distant
recurrence rate (38.2% vs 38%, RR 1.02, 0.92–1.14) or breast cancer mortality (34.4%
vs 33.7%, RR 1.06, 0.95–1.18) in patients treated with NACT compared to adjuvant
chemotherapy at 15-year follow-up.2 Furthermore, despite NACT leading to a higher
frequency of breast-conserving therapy (BCT) (65% vs 49%) compared to adjuvant
chemotherapy, there was also an associated increased risk of local recurrence in
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patients (21.4% vs 15.9%; RR 1.37, 1.17–1.61). Similarly,
the NSABP B-18 study showed equivalent disease-free sur
vival (DFS), distant disease-free survival, and OS in patients
receiving pre-operative and post-operative chemotherapy
(OS; p=0.99, 0.70, and 0.83, respectively), however with
more women able to achieve BCT in the pre-operative che
motherapy group.3 One group that did experience a superior
DFS and OS in those receiving NACT was patients who had
a pathologic complete response (pCR). Altogether, the afore
mentioned studies suggest NACT provides therapy that is
equivalent to adjuvant therapy and notably demonstrates
a survival advantage in those who have a complete response.4

Association of Pathological Complete
Response with Survival Outcomes
Response to neoadjuvant therapy provides important prognos
tic information and helps guide adjuvant therapy recommen
dations. It allows for an in vivo human model system to
explore the efficacy of chemotherapy and leads to a better
understanding of breast cancer biology. pCR, as defined by the
FDA, is the absence of residual invasive cancer on hematox
ylin and eosin evaluation of the complete resected breast
specimen and all sampled regional lymph nodes following
completion of NACT (ypT0/is ypN0).5 pCR has been shown
to correlate with improved survival as demonstrated in the
CTNeoBC pooled analysis.6 This pooled analysis of 12 inter
national trials and 11,955 patients demonstrated improved
event-free survival (EFS) and OS with ypT0/Tis ypN0 pCR
with HR of 0.48 and 0.36, respectively. The association with
pCR and long-term outcomes was strongest in triple-negative
breast cancer (TNBC) patients (EFS HR 0.24, OS HR 0.16)
and HER2-positive, hormone-receptor negative patients who
received trastuzumab (EFS HR 0.15, OS HR 0.08). Several
other trials have also demonstrated that the subset of ERnegative and HER2-positive breast cancers who achieved
a pCR after NACT have a notable survival advantage when
compared to those with residual disease.7,8 The presence of
residual disease after NACT portends an increased risk of
recurrence and further adjuvant therapy can be given to
patients with HER2-positive or triple-negative breast cancer
to prevent distant disease recurrence.

diagnosis. Prior to undergoing NACT, the following is
required: physical examination, breast imaging including
ultrasound, mammogram, and core biopsy, and a biopsy of
the lymph node with clip/marker placement. Prior to each
cycle of chemotherapy, a physical examination should be
performed to monitor response to therapy. There are rare
occasions where the tumor has little response or grows
despite NACT, necessitating a change in therapy or pro
ceeding to earlier surgery. Therefore, periodic physical
examinations are crucial. At the conclusion of therapy,
repeat breast imaging including a mammogram and ultra
sound are performed. The following will discuss the key
indications for neoadjuvant therapy (Table 1).

Hormone Receptor-Positive Breast
Cancer
Hormone receptor (HR)-positive breast cancer accounts
for approximately 75% of new breast cancer diagnoses.9
Most frequently, these patients will receive cytotoxic che
motherapy for their neoadjuvant treatment, although there
are situations where NET is preferred over NACT. While
NACT confers the greatest advantage in HER2-positive
breast cancer and TNBC, the rates of pCR are lower in
luminal cancer, averaging 10–20% of cases.5,8 This sug
gests that luminal cancers are less sensitive to chemother
apy compared to other subtypes and a potential alternative
to cytotoxic chemotherapy is NET. A meta-analysis of 20
studies involving 3490 patients compared combination
chemotherapy to NET with aromatase inhibitors (AI).10
Although both groups had a similar clinical response rate
(OR, 1.08; 95% CI, 0.50–2.35; P=0.85), radiological
Table 1 Indications for Consideration of Neoadjuvant
Chemotherapy
*Hormone-receptor positive breast cancer
High-risk HER2-positive breast cancer
High-risk triple-negative breast cancer
Inflammatory breast cancer
Locally advanced tumors breast cancers
Clinically node-positive breast cancers

Clinical and Radiological Assessment in
the Neoadjuvant Approach
Neoadjuvant chemotherapy allows for visualization of
a marked reduction in tumor size, thus it is critical to
accurately mark the primary tumor at the time of
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Patients with contraindications to surgery including pregnancy or
venous thromboembolism (VTE)
Delayed elective surgical plans due to pandemic or other elective
procedures
Note: *In certain circumstances.

Breast Cancer: Targets and Therapy 2021:13

Dovepress

response rate (OR, 1.38; 95% CI, 0.92–2.07; P = 0.12),
and BCS rate (OR, 0.65; 95% CI, 0.41–1.03; P = 0.07),
there were lower toxicities associated with AI monother
apy. These results suggest that in the face of similar out
comes, NET may be a preferred option in light of
increased tolerability.
Tamoxifen is a long-standing treatment for HR-positive
breast cancer. However, issues including tamoxifen resis
tance and serious adverse effects such as thromboembo
lism and endometrial cancer necessitate the use of other
viable options. While earlier trials utilized tamoxifen,
recent studies demonstrate better outcomes with AI in
postmenopausal women. The P024 trial is the largest trial
comparing neoadjuvant tamoxifen and letrozole in HRpositive postmenopausal women who were ineligible for
breast-conserving surgery (BCS). Letrozole led to
a significantly greater objective response rate (ORR)
(55% vs 36%, p<0.0010) and rate of BCS (45% vs 35%,
p=0.022) compared to tamoxifen.11 Both the PROACT and
IMPACT trial compared neoadjuvant tamoxifen and
anastrozole.12,13 In the PROACT trial, anastrozole was
superior to tamoxifen (36.6% vs 24.4% p=0.04) based on
objective response measured by ultrasound evaluation.
Although there was no difference in ORR between both
arms in the IMPACT trial, among patients who were not
BCS candidates at study entry, treatment with anastrozole
resulted in increased BCS rate compared to the tamoxifen
arm (46% vs 22%; p=0.03). Based on these enhanced
outcomes with AI compared to tamoxifen, the ACOSOG
Z1031 trial was designed to evaluate clinical outcomes
among the AIs exemestane, letrozole, and anastrozole.14
In terms of ORR and BCS, there was no significant dif
ference found between the different types of AIs, suggest
ing they are largely interchangeable.
Despite the advantages of neoadjuvant AI therapy,
there are no clear guidelines about the duration of treat
ment. Although most NET randomized trials have
a treatment duration of 3 to 4 months based on studies of
tamoxifen and chemotherapy, there is concern that this
might not be sufficient to achieve optimal tumor
shrinkage.15,16 In clinical studies involving the administra
tion of 12 months of NET, the ORRs ranges from 76.8 to
95%, and the rate of BCS was 45 to 87.5%.15,17 In con
trast, the PROACT and IMPACT trials used a duration of 3
months and reported an ORR of 49.7% and 37%, respec
tively, and BCS rates of 43% and 44%, respectively.12,13
Similar results were observed in a study utilizing exemes
tane therapy that evaluated tumor size at 3 and 6 months.18
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Overall response was 58.7% at 3 months and 68.3% at
final clinical palpation (p=0.001). The BCS rate increased
from 61.8% to 70.6% (p=0.012). Although these studies
demonstrate that long-term NET achieves further tumor
reduction and increases BCS rates, there are concerns
that prolonging NET until maximal response increases
the risk of disease progression. Further studies will need
to be done to investigate the optimal duration of NET and
whether outcomes are not jeopardized as a result of che
motherapy exclusion.
Another area of interest is identifying reliable biomar
kers for optimal patient selection and measuring treatment
response to NET. Although pCR rates have been the stan
dard to measure efficacy of neoadjuvant therapy, they may
not be as reliable an outcome measure in HR-positive
tumors. This has led to the development of the preopera
tive endocrine prognostic index (PEPI) which combines
Ki-67 level, ER status, pathological tumor size, and node
status in the surgical specimen following NET.19 Patients
with a PEPI score of 0 have an extremely low risk of
relapse and can be exempt from adjuvant chemotherapy.
Scores of 0, 1–3, and ≥4 corresponded to a risk of relapse
of 10, 23, and 48% respectively. The PEPI score was
further validated in the ACOSOG Z1031 trial. Data at
a median follow-up time of 5.5 years showed a clear
difference in relapse-free survival with 3.7% of patients
with PEPI=0 relapsing compared to 15% with PEPI>1
(recurrence hazard ratio [PEPI = 0 vs PEPI > 0] = 0.35;
p = 0.14; 95% CI, 0.092 to 0.764).20 The ALTERNATE
trial aims to assess the validity of Ki-67 level measure
ment following four-week treatments with anastrozole,
fulvestrant, or the combination. After the initial treatment,
women with a Ki-67>10% will be switched to NACT,
while women with a PEPI=0 will proceed to receive adju
vant endocrine therapy.21 Between all the treatment arms,
no discernable differences were reported in endocrinesensitive disease rates (ESDR) or rate of breastconserving surgeries, although recurrence-free survival
data are still pending.
Other novel agents are being evaluated with regard to
their ability to improve the efficacy of NET or to overcome
de novo resistance to NET. One such class of drugs is
CDK4/6 inhibitors (CDKI) that have been shown to
enhance the activity of AI in advanced disease. In the
neoMONARCH and PALLET trials, the combination of
NET with a CDKI (abemaciclib and ribociclib, respec
tively) resulted in decreased levels of Ki-67, although
this did not correspond to a significant improvement in
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clinical response rate in the PALLET trial.22,23 The
CORALLEEN trial was a randomized Phase II trial inves
tigating ribociclib plus letrozole vs chemotherapy in post
menopausal women with luminal B HR-positive breast
cancer.24 The proportion of patients achieving a PEPI of
0 was 22.4% with ribociclib and letrozole and 17.3% with
chemotherapy, demonstrating the efficacy of NET com
bined with CDKIs in luminal B patients as well. Further
research is needed to elucidate the potential role of CDKIs
in the neoadjuvant setting.
The eventual development of endocrine resistance with
endocrine therapy has led to increased interest in phospha
tidylinositol 3-kinase (PI3K) inhibitors, including alpelisib
and taselisib, due to the involvement of PI3K-AKT-mTOR
pathway upregulation in endocrine resistance. The
LORELEI trial is a phase II trial randomizing 334 patients
with HR-positive breast cancer to neoadjuvant therapy
with letrozole plus taselib or letrozole alone. The addition
of taselisib to letrozole was associated with a higher pro
portion of patients achieving an ORR compared to letro
zole alone (50% vs 39%, p=0.049).25 These results suggest
that PI3K inhibitors do have a role in enhancing the
effectiveness of NET in HR-positive breast cancer.
Another novel therapeutic approach involves immu
notherapy, which has demonstrated promising results in
the neoadjuvant treatment of TNBC. Checkmate 7FL
(NCT04109066) is an ongoing Phase 3 study evaluating
nivolumab versus placebo in combination with NACT.
Patients will undergo surgery and receive either nivolumab
or placebo with endocrine therapy in the adjuvant
setting.26 Primary endpoints are pCR and event-free survi
val. KEYNOTE-756 is another phase 3 study utilizing
neoadjuvant pembrolizumab (versus placebo) and che
motherapy followed by pembrolizumab (versus placebo)
plus endocrine therapy in the adjuvant setting.27 However,
to date, there are no data supporting a role for immu
notherapy in the treatment of HR-positive tumors.

High-Risk HER2-Positive Breast
Cancer
HER2-positive breast cancer is an aggressive subtype that
is due to persistent activation of signaling of the human
epidermal growth factor receptor 2 (HER2) pathway and
accounts for 15% of all breast cancers.28 Patients with
HER2-positive breast cancer who receive NACT have
a higher rate of pCR with a combination of cytotoxic
chemotherapy and targeted therapy compared to those
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who receive adjuvant chemotherapy. A 2016 metaanalysis of 5800 patients with HER2-positive breast can
cer receiving NACT showed that those who achieved
a pCR had an improved OS and event-free survival
(EFS) compared to those who did not.29 Neoadjuvant
chemotherapy for HER2-positive breast cancer includes
administration of chemotherapy, either anthracycline
based or non-anthracycline based, with anti-HER2 mono
clonal antibodies (trastuzumab and pertuzumab). It
remains controversial regarding the use of an anthracy
cline in the neoadjuvant setting for HER2-positive breast
cancer.
Historically, anthracycline-based regimens have been
used for treatment of HER2-positive breast cancer and
are often reserved for high-risk subgroups such as those
with lymph node involvement or a young age. In the
NSABP B-41 study, patients with HER2-positive breast
cancer were assigned to receive four cycles of doxorubicin
and cyclophosphamide every three weeks followed by
weekly paclitaxel-trastuzumab and were found to have an
overall pCR rate of 49%. In the lymph node-positive
patients, the pCR rate was 43%.30
Subsequent studies have shown that treatment with an
anthracycline is not critical. In the TRAIN-2 study, patients
with early-stage HER2-positive breast cancer were treated
with adjuvant chemotherapy, either an anthracyclinecontaining regimen or a non-anthracycline-based chemother
apy, combined with trastuzumab and pertuzumab. The pCR
rate did not differ significantly between these two arms (67%
in the anthracycline arm vs 68% in the non-anthracycline
arm), and the 3-year EFS (94% vs 93%), OS (98% vs 98%)
were equivalent.31 No subgroup of patients benefited from
the inclusion of an anthracycline and there were more side
effects in the anthracycline-containing arm including higher
rates of febrile neutropenia (10% vs 1%) and a significant
decline in LVEF (36% vs 22%). In the randomized phase II
TRYPHAENA study, the nonanthracycline-containing regi
mens plus trastuzumab and pertuzumab resulted in a pCR of
64% compared to a pCR of 55% among those treated with an
anthracycline-based regimen (FEC-THP) containing trastu
zumab and pertuzumab and also resulted in lesser hematolo
gic toxicity.32 Given the aforementioned studies, a taxane and
carboplatin-containing regimen is a reasonable alternative to
an anthracycline-containing regimen.
In addition to NACT, anti-HER2 therapy is routinely
added, with trastuzumab representing the first targeted antiHER2 drug. In a meta-analysis of 2000 patients with HER2positive disease, the addition of trastuzumab to NACT
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increased the pCR from 23 to 40%.8 Similarly, in the phase II
NOAH trial, patients treated with NACT and trastuzumab
had an increase in pCR rate to 38% compared to 19% with
NACT alone.33 Long-term follow-up demonstrated improved
EFS in the group that received trastuzumab (43 vs 58%; HR
0.64, 95% CI 0.544–0.930).33 Despite the effectiveness of
trastuzumab, there are clinical concerns about the develop
ment of acquired resistance over a period of time. In order to
eradicate resistance, the addition of pertuzumab to trastuzu
mab has been investigated. In the Phase 2 NeoSphere trial,
patients with locally advanced and inflammatory HER2positive breast cancer had a significantly improved pCR in
the group receiving pertuzumab and trastuzumab plus doc
etaxel (45.8%) compared to the other three groups who
received trastuzumab plus docetaxel (29%, p=0.0141), pertu
zumab plus trastuzumab (16.8%), or pertuzumab and doce
taxel (24%).34 A meta-analysis of six trials involving
approximately 2000 patients demonstrated an improved
pCR rate of 16–19% in patients receiving dual blockade,
irrespective of the chemotherapy backbone (RR 1.37, 95%
CI 1.23–1.53, p < 0.0001).35 These findings suggest a role for
the addition of pertuzumab to NACT and trastuzumab.
For patients with residual disease after neoadjuvant ther
apy, T-DM1 in the adjuvant setting can decrease the risk of
recurrence. This recommendation is based on the results of
the KATHERINE trial, in which 1486 HER2-positive patients
with residual invasive disease after neoadjuvant therapy with
a taxane and trastuzumab or dual HER2-blockade were ran
domized to receive adjuvant T-DM1 or trastuzumab. T-DM1

Hyder et al

administration improved 3-year invasive disease-free survival
(88% vs 77%; HR =0.50; 95% CI, 0.39–0.64; P<0.001) and
the distant recurrence as the first invasive-disease event
(10.5% vs 15.9%).36 For those patients that achieve pCR
following HER2-directed therapy, adjuvant trastuzumab is
continued with or without pertuzumab to complete twelve
months of HER2-directed therapy (Figure 1).
The benefit of adding trastuzumab to the adjuvant
chemotherapy regimen has been proven in the BCIRG
006 study which demonstrated that both doxorubicincyclophosphamide-docetaxel plus trastuzumab (AC-T
plus trastuzumab) and docetaxel-carboplatin-trastuzumab
(TCH) were superior to AC-T with respect to DFS (DFS
at 5 years; 84% AC-T plus trastuzumab vs 81% TCH vs
75% AC-T). Estimated OS was 92%, 91%, and 87%,
respectively.37 The APHINITY trial demonstrated an
improvement in 3-year IDFS with the addition of pertuzu
mab to adjuvant trastuzumab (94.1% with pertuzumab vs
93.2% with placebo, HR 0.81, 95% CI 0.66–1.00;
p=0.045).38 Among patients with LN-positive breast can
cer, those randomized to receive adjuvant dual HER2
blockade for 1 year following chemotherapy had improved
3-year IDFS by 1.8% (92 vs 90.2%, HR 0.77, 95% CI
0.62–0.96; p=0.02). In the cohort with node-negative dis
ease, the 3-year rate of invasive disease-free survival
(IDFS)\was 97.5% in the pertuzumab group and 98.4%
in the placebo group (HR1.13; 95% CI 0.68–1.86;
P=0.64). These results suggest that in the adjuvant treat
ment of HER2-positive patients, dual HER2 blockade with

Figure 1 Treatment algorithm for adjuvant treatment in HER2+ patients.
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trastuzumab plus pertuzumab is valid options for nodepositive disease.
The NCCN Guidelines suggest all HER2-positive
breast cancer should be treated with a combination of
adjuvant chemotherapy with trastuzumab.39 The majority
of adjuvant trastuzumab studies incorporated anthracy
clines with or without taxanes. The decision on the type
of chemotherapy backbone should be tailored based on the
risk–benefit ratio for the individual patient. For example,
in the aforementioned BCIRG 006 trial, although TCH and
AC-T plus trastuzumab had similar DFS and OS, the
former showed a more favorable cardiac safety profile.36
This chemotherapy regimen would be more suitable for
patients with cardiac risk factors such as hypertension,
decreased left ventricular ejection fraction, and older age.
For HER2-positive tumors <2cm (T1a,bN0M0), retrospec
tive studies not only demonstrate a benefit for the admin
istration of trastuzumab but also suggest that there is
a significant risk of relapse and adverse prognosis if trea
ted with chemotherapy alone.40–43 Therefore, the NCCN
guidelines do recommend that these patients receive tras
tuzumab in combination with chemotherapy.

High-Risk Triple-Negative Breast
Cancer
Triple-negative breast cancer (TNBC) accounts for 15% of
all breast cancer and is characterized by the lack of expres
sion of ER, PR, and HER2. This subtype of breast cancer
tends to be very aggressive with early recurrence and
worse OS when compared to other breast cancer
subtypes.44 Neoadjuvant chemotherapy is a standard
approach for any tumor greater than 2 cm or with lymph
node involvement. About 35 to 40% of TNBC patients
who receive NACT have a pCR which is a surrogate
marker for survival.45 However, patients who do not
achieve a pCR have poorer outcomes.46 At the 2018
SABCS meeting, a meta-analysis of 52 studies, including

over 27,000 patients, demonstrated significantly superior
5-year EFS and OS in patients with pCR compared with
residual disease (RD), with the greatest difference in the
TNBC cohort (90% vs 57%).47
Early TNBC with tumor sizes ≤0.5 cm (T1a) or between
0.6–1.0 cm (T1b) without lymph node involvement have
a good prognosis without the addition of chemotherapy.
A study involving 363 patients with T1a,bN0 TNBC mea
sured the five-year distant recurrence-free survival (DRFS)
between patients treated with adjuvant chemotherapy to
those who were not. Patients with untreated T1a and T1b
TNBC had a five-year DRFS 93% and 90% compared to
treated T1a and T1b TNBC DRFS 100% and 96%,
respectively.48 Therefore, the decision to administer che
motherapy can be made on a case-by-case basis. However,
for tumor size >1 cm with or without lymph node involve
ment, systemic chemotherapy is the recommended backbone
of treatment. Standard chemotherapy regimens for TNBC
are a combination of anthracyclines, taxanes, and alkylators.
The Anthracycline in Breast Cancer (ABC) analysis evalu
ated anthracycline-based regimens versus six cycles of TC
in the adjuvant setting and found that overall, patients treated
with anthracycline did slightly better (four-year IDFS of
91% vs 88% for TC).49 The benefit of adding the anthracy
cline was substantial only in node-positive TNBC and HRpositive patients with four or more involved nodes.
Although the ABC trial was performed in the adjuvant
setting, the results are commonly extrapolated for manage
ment in the neoadjuvant setting.
Platinum agents such as carboplatin have been investigated
in the neoadjuvant setting and have consistently been shown to
improve pCR rates in multiple trials including CALGB
40,603, GeparSixto, and BrighTNess (Table 2). In the
CALGB 40,603 study, TNBC patients were randomized to
receive bevacizumab, carboplatin, or both in combination with
standard taxane/anthracycline-based NACT.50 Although the
addition of carboplatin to standard NACT increased rates of

Table 2 Neoadjuvant Trials in Triple-Negative Patients
Neoadjuvant Regimens with Carboplatin for Triple-Negative Breast Cancer
Trial

Phase

# of Patients

Investigational Arm

pCR (%) with Platinum vs without

EFS Improved

CALGB 40,603
BrighTNess

2
3

443
634

T →AC + Bev
T ± V → AC

54 vs 41 (p=0.003)
58 vs 31 (p<0.001)

No
NA

GeparSixto

2

595

T + A+ Bev

53 vs 43 (p=0.015)

Yes

GEICAM/2006-03

2

189

EC → T + Cb

30 in both arms

NA

Abbreviations: A, anthracycline; Bev, bevacizumab; C, cyclophosphamide; Cb, carboplatin; E, epirubicin; Nab-pac, nabpaclitaxel; pCR, pathologic complete response; T,
taxane; V, veliparib.
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pCR from 39% to 49%, it did not result in improved 5-year
EFS and OS. In contrast, the GeparSixto trial demonstrated
that the addition of carboplatin significantly improved pCR
(53% vs 43%, p=0.005) which resulted in higher rates of
3-year EFS (86% vs 76%, HR of 0.60, 95% CI 0.34–0.93).51
In the BrighTNess study, patients with stage II to III TNBC
were randomized to weekly paclitaxel with or without carbo
platin and veliparib (an oral PARP inhibitor) followed by
doxorubicin and cyclophosphamide. The addition of carbopla
tin improved the pCR rate from 31% to 58% while the addition
of veliparib had no effect on pCR rates.52 Long-term outcome
data of the BrighTNess trial are still pending.
Interestingly, these studies also demonstrate that TNBC
patients are likely to derive benefit from the addition of
carboplatin regardless of BRCA status. In BrighTNess, the
addition of carboplatin increased the pCR rate in BRCAwildtype patients from 29 to 59%, versus an increase from
41 to 50% in BRCA carriers.51 Additionally, in
GeparSixto, there was an absolute improvement in DFS
at 35 months with the addition of carboplatin, which was
greater in BRCA-wildtype patients (85 versus 74%; HR
0.53; 95% CI 0.29–0.96), versus in BRCA-mutated
patients (86 versus 82%).53,54 Although the addition of
platinum to a NACT regimen leads to higher pCR rates,
the associated toxicities often necessitating dose reduc
tions or cycle eliminations and the contradictory longterm survival results make it a controversial choice.
The recent approval of immune-checkpoint inhibitors
(ICI) combined with chemotherapy in programmed deathligand 1 (PD-L1)-positive metastatic TNBC patients has
prompted interest in their role in the neoadjuvant setting.55
Three clinical trials have shown promising data about the
combination of immunotherapy with NACT (Table 3). In
Investigation of Serial Studies to Predict Your Therapeutic
Response through Imaging and Molecular Analysis 2
(I-SPY2), pembrolizumab (a PD-1 inhibitor) was added

to standard NACT to evaluate its success in a confirmatory
randomized phase II trial.56 Pembrolizumab tripled the
estimated pCR rates in TNBC (60% with pembrolizumab
versus 22% with placebo). The Phase III KEYNOTE-522
study examined the addition of pembrolizumab to NACT,
consisting of paclitaxel and carboplatin followed by dox
orubicin or epirubicin and cyclophosphamide, resulted in
an improvement in overall pCR rate from 51 to 65%
(p<0.001).57 However, additional data about EFS are
pending final analysis. The phase III IMpassion031 trial
examined the addition of atezolizumab (a PD-L1 inhibitor)
to NACT with weekly nab-paclitaxel followed by doxor
ubicin and cyclophosphamide which resulted in improved
pCR rate from 41 to 58% (p=0.0044).58 Unfortunately, this
study was not powered to address EFS. Both KEYNOTE522 and IMpassion031 showed improved pCR in the PDL1 positive groups, but there was a treatment effect in both
the PD-L1 positive and negative groups. Interestingly, the
NeoTRIPaPDL1 study did not demonstrate statistically
significant improved pCR rates with the addition of atezo
lizumab to NACT consisting of nab-paclitaxel and
carboplatin.59
There has been interest in identifying subsets of TNBC
patients who may benefit from less chemotherapy due to
increased sensitivity to specific agents. One subset of
patients who may respond to targeted therapy and require
less chemotherapy is those with germline BRCA muta
tions that are sensitive to poly ADP-ribose polymerases
(PARP) inhibitors. Olaparib and talazoparib are two PARP
inhibitors currently approved for patients with metastatic
breast cancer and germline mutations. A phase II pilot
study involved 20 patients (10 TNBC) with germline
BRCA mutations receiving neoadjuvant talazoparib in
which pCR was achieved in 53% prompting the explora
tion of the role of PARP monotherapy in this subset of
patients.

Table 3 Neoadjuvant Trials with Immunotherapy in Triple-Negative Patients
Neoadjuvant Regimens with Immunotherapy in Triple-Negative Breast Cancer
Trial

Phase

# of
Patients

Chemotherapy
Regimen

Immune Checkpoint
Inhibitor

pCR(%) with ICI Versus
without

I-SPY2
KEYNOTE-522

2
3

250
602

T → AC
Cb + T → AC

Pembrolizumab
Pembrolizumab

60% vs 22%
65% vs 51% (p<0.001)

IMpassion031

3

333

Nab-pac → AC

Atezolizumab

58% vs 41% (p=0.004)

NeoTRIPaPDL1

3

280

Cb + Nab-pac

Atezolizumab

44% vs 41% (p=0.66)

Abbreviations: A, anthracycline; Bev, bevacizumab; C, cyclophosphamide; Cb, carboplatin; Nab-pac, nabpaclitaxel; pCR, pathologic complete response; T, taxane; V,
veliparib.
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In the case of residual disease after NACT, adjuvant
capecitabine is another potential therapy to further reduce
the risk of breast cancer recurrence. The CREATE-X trial
randomized 910 patients with HER2-negative disease trea
ted with standard NACT and with residual disease to
adjuvant capecitabine for six to eight cycles versus obser
vation only.60 Adjuvant radiotherapy was given if indi
cated. Full analysis demonstrated an improvement in
5-year DFS from 69.8% to 56.1% with capecitabine in
the TNBC subset. These findings further support the use
of NACT instead of adjuvant chemotherapy in TNBC
patients, as those patients who achieve pCR have
improved outcomes and those that do not achieve pCR
clearly can benefit from the addition of adjuvant
capecitabine.

Inflammatory Breast Cancer
Inflammatory breast cancer (IBC) is a rare form of breast
cancer comprising 2.5% of all breast cancers in the United
States.61 The main role of neoadjuvant therapy in the
setting of IBC is to be able to surgically treat with mod
ified radical mastectomy without leaving positive margins,
thereby limiting the risk of systemic metastases.
The current standard of neoadjuvant therapy in IBC is
determined by the subtype of breast cancer with regard to
expression of ER, PR, and HER2. Neoadjuvant therapy
for ER-positive and TNBC remains anthracycline and
taxane-based chemotherapy. In a large retrospective
study, of the 178 IBC patients treated with anthracyclinebased chemotherapy followed by local treatment with
irradiation, with or without mastectomy, 15-year survival
was the greatest in patients who accomplished pCR
(44%), versus partial response (31%).62 In a cohort
study of 68 patients with IBC, treatment with either
NACT consisting of FEC (cyclophosphamide, epirubicin
and 5-fluorouracil) or FAC (cyclophosphamide, doxorubi
cin and 5-fluorouracil), followed by surgery, adjuvant
therapy, and radiotherapy resulted in overall 5-year survi
val rate of 44% and 10-year survival of 32%.63 These
results confirmed that IBC patients obtained significant
long-term survival benefit from combined-modality treat
ment. The standard of care in neoadjuvant treatment of
IBC is a sequential regimen using anthracyclines then
taxanes.
Given that IBC has a higher proportion of HER2positive tumors as compared to noninflammatory cancers
or other locally advanced cancers, anti-HER2 treatments
have an integral role in the neoadjuvant setting. In the
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NeOAdjuvant Herceptin (NOAH) trial, HER2-positive
IBC had a pCR of 54.8% after treatment with neoadjuvant
trastuzumab combined with chemotherapy.64 A subsequent
subgroup analysis comparing patients that received
a combination of trastuzumab plus NACT vs NACT
alone had a better 5-year event-free survival (64% vs
24%) and 5-year OS (74% vs 44%).33

Locally Advanced Breast Cancer or
Clinically Node-Positive Disease
Patients with T3 or T4 breast lesions or with multiple
axillary lymph nodes involved are candidates for NACT
as they are often not amenable to upfront resection and
they would not be candidates for breast conservation.
Additionally, patients with limited clinically nodepositive disease are also eligible for NACT, as it often
converts cN1 patients to pN0, especially in patients with
aggressive subtypes.
Neoadjuvant therapy was initially pursued in patients with
locally advanced breast cancers, typically at least T3 (≥5 cm in
largest dimension), in which only larger, involved surgeries
would have been considered. Patients with locally advanced
breast cancers or inoperable breast cancers have traditionally
been excluded from larger randomized control trials assessing
the effect of neoadjuvant therapy on surgical options and
outcomes. However, neoadjuvant therapy in this group
of patients is recommended by major cancer society governing
bodies ASCO65 and NCCN.39 The rationale is that neoadju
vant systemic therapy can lead to downstaging of the primary
tumor to increase operability or potential cosmesis of breastconserving therapy (BCT), as well as to more rapidly treat
subclinical distant micrometastases. However, there have
been several large randomized controlled trials that have
clearly demonstrated improved rates of BCT therapy with
neoadjuvant therapy compared to adjuvant therapy in earlier
stage operable breast cancers. This data has been extended
to guide management of more locally advanced disease.
NSABP B-18 randomized 1523 women with stage I–
II disease to either pre-operative or post-operative AC.66 It
found that more patients receiving neoadjuvant ther
apy were able to receive lumpectomy, compared to those
receiving adjuvant therapy (67.8% vs 59.8%). The ECTO
trial assessed patients with primary operable breast cancer
(T2–3N0–1M0) who received neoadjuvant systemic therapy
(in this case AT x 4 cycles, followed by CMF for 4 cycles)
and compared them to those receiving surgery followed by
adjuvant therapy.67 There was a significant reduction in the
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requirement for mastectomy in patients who received neoad
juvant therapy. 65% of patients receiving neoadjuvant therapy
were able to receive BCS compared to 34% of women in the
primary surgery arms (p<0.001).
More importantly, several studies have performed second
ary analyses which demonstrated that patients who were not
candidates for breast-conserving surgery at diagnosis were
able to become candidates for BCS after neoadjuvant
therapy. In the CALGB 40,601 study, breast-conserving sur
gery candidacy was assessed of patients with stage II–III
HER2+ breast cancer before and after neoadjuvant
therapy.68 43% of the patients who were not initially candi
dates for BCS converted to candidates for BCS after neoadju
vant therapy. In the more recent BrighTNess RCT, 604
patients with stage II–III TNBC were assessed for BCS can
didacy before and after neoadjuvant therapy.69 Of the 141
patients who were deemed BCS ineligible at baseline, 53.2%
then converted to BCS eligible after neoadjuvant therapy with
ACT ± carboplatin and/or veliparib.
Traditionally, the standard approach to clinically nodepositive breast cancer is with axillary lymph node dissec
tion (ALND). However, ALND has been associated with
higher surgical complications and long-term symptomatic
risks of lymphedema, limited mobility in that extremity,
and neuropathy which can greatly lessen quality of
life. Currently, randomized controlled trials examining
the question of whether neoadjuvant therapy can decrease
the need for ALND are ongoing. However, guidelines still
recommend upfront systemic therapy for clinically nodepositive disease to permit for less extensive surgery on the
axilla based on data from other trials.1 In a prospective
study of 288 node-positive stage II–III breast cancer
patients receiving neoadjuvant therapy, patients who were
clinically node-negative after treatment were candidates
for sentinel lymph node biopsy (SLNB).70 68% of those
who underwent surgery became clinically node-negative
after NACT and were able to undergo an SLNB as
opposed to ALND. Of the 128 SLNB cases, 48% were
able to avoid a subsequent ALND, which supports the role
of neoadjuvant therapy for reducing the need for ALND
among patients with metastases. One significant concern
with neoadjuvant therapy followed by SLNB instead of
ALND in patients who were baseline clinically nodepositive is the potential false-negative rate of
SLNB; i.e. no evidence of nodal metastases on sufficient
SLNB, but later found to have nodal metastases on an
ALND. The ACOSOG Z1071 trial specifically addressed
this concern. The initial multi-institutional trial
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demonstrated that the false-negative rate of SLNB after
NACT was 12.6%.71 However, a secondary analysis of the
study showed that in patients who had a clip placed in the
positive node at the initial biopsy and had an SLNB of at
least 2 nodes, that the clip was recovered within the SLN
specimen 83.7% of the time,72 Another study showed that
in 118 patients undergoing SLNB followed by ALND, that
if the clipped node was included in the SLNB that the
false-negative rate decreased greatly, from 10.1% to
1.4%.73 Thus, a reasonable approach to clinically nodepositive disease is to place a clip during biopsy, pursue
neoadjuvant therapy, and then if then downstaged to clini
cally node-negative disease move forward with an
SLNB. SLNB should include the clip to decrease the
false-negative rate. If SLNB is positive for nodal metas
tasis, then ALND can be performed. If SLNB is nega
tive, potential complications and sequelae of ALND can be
avoided.

Patients with Contraindications for
Surgery
Neoadjuvant chemotherapy or endocrine therapy may be
a suitable option for patients who have contraindications to
undergo surgery at the time of diagnosis or in situations in
which delays in elective surgeries are encountered or
necessitated, such as during a pandemic, during pregnancy
or after a recent venous thromboembolism.
There are several absolute contraindications to upfront
surgery and/or radiation. These typically are due to inabil
ity to achieve appropriate margin control with BCS or
inability of the patient to tolerate radiation therapy.
Some of the absolute contraindications to initial BCS are
multicentric disease where tumors are located in different
quadrants of the breast and patients with diffuse malig
nant-appearing microcalcifications not confined to a single
localized area. Due to the multicentric or diffuse nature of
these presentations, a lumpectomy or smaller surgery is
often not able to be completed until downstaging by
neoadjuvant therapy. Patients who have had prior radia
tion therapy to the affected breast also have an absolute
contraindication to BCT. Frequently, these patients have
had previous radiation in the setting of treatment of
Hodgkin’s Lymphoma or previous breast cancer. If they
were considered for further radiation, these patients would
receive unacceptably high doses of radiation, making
BCT infeasible. An additional absolute contraindication
to BCT is a patient diagnosed in the first or second

submit your manuscript | www.dovepress.com

DovePress

207

Dovepress

Hyder et al

trimester of pregnancy and where a pregnancy termination
is not desired or feasible. This is because therapeutic
radiation during pregnancy is teratogenic to the fetus.
Typically, radiation is given within 3–8 weeks of lumpect
omy. Waiting a longer period of time, such as greater than
20 weeks, can significantly decrease local recurrence-free
survival and breast cancer-specific survival, as compared
to waiting 4–8 weeks after therapy.74 In this situation, it is
reasonable to consider neoadjuvant therapy. For patients
diagnosed in the third trimester, they may be able to move
forward with upfront BCT as radiation therapy may be
administered after delivery of the baby.
Some relative contraindications to initial BCT are
those that are related to vascular changes of the patient,
which increase the risk of complications or the risk of
inadequate cosmesis of the breast. Traditionally, patients
with collagen vascular disease (CVD) have been classified
as having a relative contraindication to BCT due to poor
vasculature and cutaneous friability, making radiation
complications more likely. However, there have been
multiple studies that have shown that the increased risk
of radiation complications of CVD patients is only in
scleroderma patients.75,76 This is not seen in other patients
with CVD. Another relative contraindication to initial sur
gery is an insufficient tumor-to-breast ratio (i.e. a large
tumor in a small breast), which would not allow for
acceptable cosmetic result.77 In these cases, neoadjuvant
systemic therapy can allow for downstaging of the tumor
and allow for a more amenable tumor to breast size ratio
and improved cosmetic outcome. Other relative contra
indications to primary surgery and radiation may be addi
tional medical or social issues; such as recent
thromboembolism requiring anticoagulation, temporary
medical unfitness, or delay of non-urgent procedures
given medical system strain during a pandemic. In these
cases, NACT or NET – if clinically appropriate – can help
to manage and treat the breast cancer until the patient is
able to receive surgery and radiation.

Conclusion
The landscape of neoadjuvant therapy continues to evolve.
Advances in systemic therapies administered in the neoad
juvant setting have resulted in increased suitability for
subsequent surgeries. Clinical trials continue to investigate
other therapies (ICI, PI3K inhibitors, mTOR inhibitors)
that can be utilized for the different subtypes of breast
cancer. The I-SPY2 provides a unique opportunity to eval
uate novel agents added to standard neoadjuvant therapy in
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small study populations with an earlier endpoint of pCR.
This allows investigational drugs with a high probability
of efficacy to move on to phase III studies more rapidly.78
Another area of interest is developing biomarkers that can
be predictors and prognosticators of response to neoadju
vant treatment. Biomarkers (TIL, tumor PD-L1, germline
BRCA) can identify patients likely to achieve pCR, predict
who can forgo surgery, and detect minimal residual disease
(ctDNA and circulating tumor cells). Understanding the
clinical, genetic, and molecular profiles in breast cancer
leads to the development of validated predictive and prog
nostic tools that helps individualize treatment plans for
these patients.

Author Contributions
All authors made a significant contribution to the work
reported, whether that is in the conception, study design,
execution, acquisition of data, analysis and interpretation,
or in all these areas; took part in drafting, revising or
critically reviewing the article; gave final approval of the
version to be published; have agreed on the journal to
which the article has been submitted; and agree to be
accountable for all aspects of the work.

Disclosure
All authors declared that there are no conflicts of interest
in this work.

References
1. DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019.
CA Cancer J Clin. 2019;69(6):438–451. doi:10.3322/caac.21583
2. Asselain B, Barlow W, Bartlett J, Early Breast Cancer Trialists’
Collaborative Group (EBCTCG). Long-term outcomes for neoadju
vant versus adjuvant chemotherapy in early breast cancer:
meta-analysis of individual patient data from ten randomised trials.
Lancet Oncol. 2018;19(1):27–39. doi:10.1016/S1470-2045(17)307775
3. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative
chemotherapy in patients with operable breast cancer: nine-year results
from National Surgical Adjuvant Breast and Bowel Project B-18.
J Natl Cancer Inst Monogr. 2001;2001(30):96–102. doi:10.1093/
oxfordjournals.jncimonographs.a003469
4. Spring LM, Fell G, Arfe A, et al. Pathologic complete response after
neoadjuvant chemotherapy and impact on breast cancer recurrence and
survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26
(12):2838–2848. doi:10.1158/1078-0432.CCR-19-3492
5. Cortazar P, Geyer CE Jr. Pathological complete response in neoadju
vant treatment of breast cancer. Ann Surg Oncol. 2015;22
(5):1441–1446. doi:10.1245/s10434-015-4404-8
6. Cortazar P, Zhang L, Untch M, et al. Pathological complete response
and long-term clinical benefit in breast cancer: the CTNeoBC pooled
analysis [published correction appears in Lancet. 2019 Mar
9;393(10175):986]. Lancet. 2014;384(9938):164–172. doi:10.1016/
S0140-6736(13)62422-8

Breast Cancer: Targets and Therapy 2021:13

Dovepress
7. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast
cancer patients with complete pathologic primary tumor and axillary
lymph node response to doxorubicin-based neoadjuvant
chemotherapy. J Clin Oncol. 1999;17(2):460–469. doi:10.1200/
JCO.1999.17.2.460
8. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of patholo
gical complete response after primary chemotherapy in relation to
hormone receptor status and other factors. J Clin Oncol.
2006;24:1037–1044. doi:10.1200/JCO.2005.02.6914
9. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer
subtypes defined by joint hormone receptor and HER2 status. J Natl
Cancer Inst. 2014;106(5):dju055. doi:10.1093/jnci/dju055
10. Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine
therapy for estrogen receptor-positive breast cancer: a systematic
review and meta-analysis. JAMA Oncol. 2016;2(11):1477–1486.
doi:10.1001/jamaoncol.2016.1897
11. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment
of postmenopausal breast cancer patients with letrozole:
a randomized double-blind multicenter study. Ann Oncol. 2001;12
(11):1527–1532. doi:10.1023/a:1013128213451
12. Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole
versus tamoxifen as preoperative therapy in postmenopausal women
with hormone receptor-positive breast cancer: the Pre-Operative
“Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer.
2006;106(10):2095–2103. doi:10.1002/cncr.21872
13. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of
postmenopausal breast cancer with anastrozole, tamoxifen, or both
in combination: the Immediate Preoperative Anastrozole, Tamoxifen,
or Combined with Tamoxifen (IMPACT) multicenter double-blind
randomized trial. J Clin Oncol. 2005;23(22):5108–5116. doi:10.1200/
JCO.2005.04.005
14. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant
comparison between letrozole, anastrozole, and exemestane for post
menopausal women with estrogen receptor-rich stage 2 to 3 breast
cancer: clinical and biomarker outcomes and predictive value of the
baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin
Oncol. 2011;29(17):2342–2349. doi:10.1200/JCO.2010.31.6950
15. Carpenter R, Doughty JC, Cordiner C, et al. Optimum duration of
neoadjuvant letrozole to permit breast conserving surgery. Breast
Cancer Res Treat. 2014;144(3):569–576. doi:10.1007/s10549-0142835-8
16. Krainick-Strobel UE, Lichtenegger W, Wallwiener D, et al.
Neoadjuvant letrozole in postmenopausal estrogen and/or progester
one receptor positive breast cancer: a phase IIb/III trial to investigate
optimal duration of preoperative endocrine therapy. BMC Cancer.
2008;8:62. doi:10.1186/1471-2407-8-62
17. Rusz O, Vörös A, Varga Z, et al. One-year neoadjuvant endocrine
therapy in breast cancer. Pathol Oncol Res. 2015;21(4):977–984.
doi:10.1007/s12253-015-9911-1
18. Fontein DB, Charehbili A, Nortier JW, et al. Efficacy of six month
neoadjuvant endocrine therapy in postmenopausal, hormone
receptor-positive breast cancer patients--a phase II trial. Eur
J Cancer. 2014;50(13):2190–2200. doi:10.1016/j.ejca.2014.05.010
19. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen
receptor-positive breast cancer based on postneoadjuvant endocrine
therapy tumor characteristics. J Natl Cancer Inst. 2008;100
(19):1380–1388. doi:10.1093/jnci/djn309
20. Ellis MJ, Suman VJ, Hoog J, et al. Ki67 proliferation index as a tool
for chemotherapy decisions during and after neoadjuvant aromatase
inhibitor treatment of breast cancer: results from the American
College of Surgeons Oncology Group Z1031 trial (alliance). J Clin
Oncol. 2017;35(10):1061–1069. doi:10.1200/JCO.2016.69.4406
21. Suman VJ, Ellis MJ, Ma CX. The ALTERNATE trial: assessing
a biomarker driven strategy for the treatment of post-menopausal
women with ER+/Her2- invasive breast cancer. Chin Clin Oncol.
2015;4(3):34. doi:10.3978/j.issn.2304-3865.2015.09.01

Breast Cancer: Targets and Therapy 2021:13

Hyder et al
22. Hurvitz SA, Martin M, Press MF, et al. Potent cell-cycle inhibition and
upregulation of immune response with abemaciclib and anastrozole in
neoMONARCH, phase II Neoadjuvant Study in HR+/HER2- breast
cancer. Clin Cancer Res. 2020;26(3):566–580. doi:10.1158/1078-0432.
CCR-19-1425
23. Johnston S, Puhalla S, Wheatley D, et al. Randomized Phase II Study
evaluating palbociclib in addition to letrozole as neoadjuvant therapy
in estrogen receptor-positive early breast cancer: PALLET trial.
J Clin Oncol. 2019;37(3):178–189. doi:10.1200/JCO.18.01624
24. Prat A, Saura C, Pascual T, et al. Ribociclib plus letrozole versus
chemotherapy for postmenopausal women with hormone
receptor-positive, HER2-negative, luminal B breast cancer
(CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol. 2020;21(1):33–43. doi:10.1016/S1470-2045(19)30786-7
25. Saura C, Hlauschek D, Oliveira M, et al. Neoadjuvant letrozole plus
taselisib versus letrozole plus placebo in postmenopausal women
with oestrogen receptor-positive, HER2-negative, early-stage breast
cancer (LORELEI): a multicentre, randomised, double-blind,
placebo-controlled, phase 2 trial. Lancet Oncol. 2019;20
(9):1226–1238. doi:10.1016/S1470-2045(19)30334-1
26. Loi S, McArthur HL, Harbeck N, et al. A phase III trial of
nivolumab with neoadjuvant chemotherapy and adjuvant endocrine
therapy in ER+/HER2- primary breast cancer: checkMate 7FL.
J Clin Oncol. 2020;38(15_suppl):TPS604–TPS604. doi:10.1200/
JCO.2020.38.15_suppl.TPS604
27. Cardoso F, Bardia A, Andre F, et al. KEYNOTE-756: a randomized,
double-blind, phase III study of pembrolizumab versus placebo in combi
nation with neoadjuvant chemotherapy and adjuvant endocrine therapy for
high-risk early-stage ER+/HER2– breast cancer [abstract] In: Proceedings
of the 2018 San Antonio Breast Cancer Symposium; Dec 4–8, 2018; San
Antonio, TX. Philadelphia (PA): AACR. Cancer Res 2019; 79(4Suppl):
Abstract nr OT3-04-03. doi: 10.1158/1538-7445.SABCS18-OT3-04-03
28. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A,
McGuire WL. Human breast cancer: correlation of relapse and sur
vival with amplification of the HER-2/neu oncogene. Science.
1987;235(4785):177–182. doi:10.1126/science.3798106
29. Broglio KR, Quintana M, Foster M, et al. Association of pathologic
complete response to neoadjuvant therapy in HER2-positive breast
cancer with long-term outcomes: a meta-analysis. JAMA Oncol.
2016;2(6):751–760. doi:10.1001/jamaoncol.2015.6113
30. Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of
neoadjuvant therapy for HER2-positive operable breast cancer (NSABP
protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol.
2013;14(12):1183–1192. doi:10.1016/S1470-2045(13)70411-X
31. van der Voort A, van Ramshorst MS, van Werkhoven ED, et al.
Three-year follow-up of neoadjuvant chemotherapy with or without
anthracyclines in the presence of dual HER2-blockade for
HER2-positive breast cancer (TRAIN-2): a randomized phase III
trial. J Clin Oncol. 2020;38S:ASCO #501.
32. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzu
mab
in
combination
with
standard
neoadjuvant
anthracycline-containing and anthracycline-free chemotherapy regi
mens in patients with HER2-positive early breast cancer:
a randomized phase II cardiac safety study (TRYPHAENA). Ann
Oncol. 2013;24(9):2278–2284. doi:10.1093/annonc/mdt182
33. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant and adju
vant trastuzumab in patients with HER2-positive locally advanced
breast cancer (NOAH): follow-up of a randomised controlled super
iority trial with a parallel HER2-negative cohort [published correc
tion appears in Lancet Oncol. 2018 Dec;19(12):e667]. Lancet Oncol.
2014;15(6):640–647. doi:10.1016/S1470-2045(14)70080-4
34. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoad
juvant pertuzumab and trastuzumab in women with locally advanced,
inflammatory, or early HER2-positive breast cancer (NeoSphere):
a randomised multicentre, open-label, phase 2 trial. Lancet Oncol.
2012;13(1):25–32. doi:10.1016/S1470-2045(11)70336-9

submit your manuscript | www.dovepress.com

DovePress

209

Hyder et al
35. Bria E, Carbognin L, Furlanetto J, et al. Impact of neoadjuvant single
or dual HER2 inhibition and chemotherapy backbone upon patholo
gical complete response in operable and locally advanced breast
cancer: sensitivity analysis of randomized trials. Cancer Treat Rev.
2014;40(7):847–856. doi:10.1016/j.ctrv.2014.05.001
36. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtan
sine for residual invasive HER2-positive breast cancer. N Engl J Med.
2019;380(7):617–628. doi:10.1056/NEJMoa1814017
37. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in
HER2-positive breast cancer. N Engl J Med. 2011;365
(14):1273–1283. doi:10.1056/NEJMoa0910383
38. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant
pertuzumab and trastuzumab in early HER2-positive breast cancer
[published correction appears in N Engl J Med. 2017
Aug 17;377(7):702][published correction appears in N Engl J Med.
2018 Oct 18;379(16):1585]. N Engl J Med. 2017;377(2):122–131.
doi:10.1056/NEJMoa1703643
39. National Comprehensive Cancer Network. Breast cancer (Version
1.2021). Available from: https://www.nccn.org/professionals/physi
cian_gls/pdf/breast_blocks.pdf. Accessed January 30, 2021.
40. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of
recurrence for patients with breast cancer who have human epidermal
growth factor receptor 2-positive, node-negative tumors 1 cm or
smaller. J Clin Oncol. 2009;27(34):5700–5706. doi:10.1200/
JCO.2009.23.2025
41. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2
overexpression/amplification in patients with small tumor size and
node-negative breast cancer. J Clin Oncol. 2009;27(34):5693–5699.
doi:10.1200/JCO.2009.22.0962
42. Theriault RL, Litton JK, Mittendorf EA, et al. Age and survival
estimates in patients who have node-negative T1ab breast cancer by
breast cancer subtype. Clin Breast Cancer. 2011;11(5):325–331.
doi:10.1016/j.clbc.2011.05.002
43. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and
erbB2 expression are superior to estrogen receptor status as risk
factors for distant recurrence in pT1N0M0 breast cancer:
a nationwide population-based study. Clin Cancer Res. 2003;9
(3):923–930.
44. Howlander N, Noone A, Krapcho M, Miller D, Brest A, Yu M. SEER
Cancer Statistics Review, 1975–2017. Bethesda, MD: National
Cancer Institute; 2017.
45. Biswas T, Efird JT, Prasad S, Jindal C, Walker PR. The survival
benefit of neoadjuvant chemotherapy and pCR among patients with
advanced stage triple negative breast cancer. Oncotarget. 2017;8
(68):112712–112719. doi:10.18632/oncotarget.22521
46. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact
of pathologic complete response on prognosis after neoadjuvant
chemotherapy in various intrinsic breast cancer subtypes. J Clin
Oncol. 2012;30(15):1796–1804. doi:10.1200/JCO.2011.38.8595
47. Spring LM, Fell G, Arfe A, et al. Pathological complete response
(pCR) after neoadjuvant chemotherapy and impact on breast can
cer recurrence and survival, stratified by breast cancer subtypes
and adjuvant chemotherapy usage: patient-level meta-analyses of
over 27,000 patients. Proceedings from the 2018 San Antonio
Breast Cancer Symposium (SABCS); December 4–8, 2018; San
Antonio, TX.
48. Vaz-Luis I, Ottesen RA, Hughes ME, et al. Outcomes by tumor
subtype and treatment pattern in women with small, node-negative
breast cancer: a multi-institutional study. J Clin Oncol. 2014;32
(20):2142–2150. doi:10.1200/JCO.2013.53.1608
49. Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast
cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132,
and NSABP B-49 (NRG oncology). J Clin Oncol. 2017;35
(23):2647–2655. doi:10.1200/JCO.2016.71.4147

210

submit your manuscript | www.dovepress.com

DovePress

Dovepress
50. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of
carboplatin and/or bevacizumab to neoadjuvant once-per-week pacli
taxel followed by dose-dense doxorubicin and cyclophosphamide on
pathologic complete response rates in stage II to III triple-negative
breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33
(1):13–21. doi:10.1200/JCO.2014.57.0572
51. Yuan Y, Lee JS, Yost SE, et al. Phase II trial of neoadjuvant carbo
platin and nab-paclitaxel in patients with triple-negative breast cancer
[published online ahead of print, 2020 Oct 24]. Oncologist. 2020.
doi:10.1002/onco.13574
52. Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP
inhibitor veliparib plus carboplatin or carboplatin alone to standard
neoadjuvant chemotherapy in triple-negative breast cancer
(BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19
(4):497–509. doi:10.1016/S1470-2045(18)30111-6
53. Hahnen E, Lederer B, Hauke J, et al. Germline mutation status,
pathological complete response, and disease-free survival in
triple-negative breast cancer: secondary analysis of the GeparSixto
randomized clinical trial. JAMA Oncol. 2017;3(10):1378–1385.
doi:10.1001/jamaoncol.2017.1007
54. Loibl S, Weber KE, Timms KM, et al. Survival analysis of carbopla
tin added to an anthracycline/taxane-based neoadjuvant chemother
apy and HRD score as predictor of response-final results from
GeparSixto. Ann Oncol. 2018;29(12):2341–2347. doi:10.1093/
annonc/mdy460
55. Garufi G, Palazzo A, Paris I, et al. Neoadjuvant therapy for
triple-negative breast cancer: potential predictive biomarkers of activ
ity and efficacy of platinum chemotherapy, PARP- and
immune-checkpoint-inhibitors. Expert Opin Pharmacother. 2020;21
(6):687–699. doi:10.1080/14656566.2020.1724957
56. Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus
neoadjuvant chemotherapy on pathologic complete response in
women with early-stage breast cancer: an analysis of the ongoing
phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6
(5):676–684. doi:10.1001/jamaoncol.2019.6650
57. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early
triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821.
doi:10.1056/NEJMoa1910549
58. Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizu
mab in combination with sequential nab-paclitaxel and
anthracycline-based chemotherapy versus placebo and chemotherapy
in patients with early-stage triple-negative breast cancer
(IMpassion031): a randomised, double-blind, phase 3 trial. Lancet.
2020;396(10257):1090–1100. doi:10.1016/S0140-6736(20)31953-X
59. Gianni L, Huang CS, Egle D, et al. Pathologic complete response
(pCR) to neoadjuvant treatment with or without atezolizumab in
triple negative, early high-risk and locally advanced breast cancer.
NeoTRIPaPDL1 michelangelo randomized study. Cancer Res.
2019;80S:SABCS #GS3-04.
60. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast
cancer after preoperative chemotherapy. N Engl J Med. 2017;376
(22):2147–2159. doi:10.1056/NEJMoa1612645
61. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH.
Trends in inflammatory breast carcinoma incidence and survival:
the surveillance, epidemiology, and end results program at the
National Cancer Institute. J Natl Cancer Inst. 2005;97(13):966–975.
doi:10.1093/jnci/dji172
62. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality
treatment of inflammatory breast carcinoma: twenty years of experi
ence at M. D. Anderson Cancer Center. Cancer Chemother
Pharmacol. 1997;40(4):321–329. doi:10.1007/s002800050664
63. Baldini E, Gardin G, Evagelista G, Prochilo T, Collecchi P,
Lionetto R. Long-term results of combined-modality therapy for
inflammatory breast carcinoma. Clin Breast Cancer. 2004;5
(5):358–363. doi:10.3816/cbc.2004.n.042

Breast Cancer: Targets and Therapy 2021:13

Dovepress
64. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemother
apy with trastuzumab followed by adjuvant trastuzumab versus
neoadjuvant chemotherapy alone, in patients with HER2-positive
locally advanced breast cancer (the NOAH trial): a randomised con
trolled superiority trial with a parallel HER2-negative cohort. Lancet.
2010;375(9712):377–384. doi:10.1016/S0140-6736(09)61964-4
65. Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemother
apy, endocrine therapy, and targeted therapy for breast Cancer: ASCO
guideline [published online ahead of print, 2021 Jan 28]. J Clin
Oncol. 2021;JCO2003399. doi:10.1200/JCO.20.03399
66. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemother
apy on the outcome of women with operable breast cancer. J Clin Oncol.
1998;16(8):2672–2685. doi:10.1200/JCO.1998.16.8.2672
67. Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of
sequential doxorubicin/paclitaxel followed by cyclophosphamide,
methotrexate, and fluorouracil and its effects on tumor response as
preoperative therapy. Clin Cancer Res. 2005;11(24 Pt 1):8715–8721.
doi:10.1158/1078-0432.CCR-05-0539
68. Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant
therapy on eligibility for and frequency of breast conservation in
stage II-III HER2-positive breast cancer: surgical results of CALGB
40601 (Alliance). Breast Cancer Res Treat. 2016;160(2):297–304.
doi:10.1007/s10549-016-4006-6
69. Golshan M, Loibl S, Wong SM, et al. Breast conservation after
neoadjuvant chemotherapy for triple-negative breast cancer: surgical
results from the BrighTNess randomized clinical trial. JAMA Surg.
2020;155(3):e195410. doi:10.1001/jamasurg.2019.5410
70. Mamtani A, Av B, Ta K, et al. How often does neoadjuvant chemother
apy avoid axillary dissection in patients with histologically confirmed
nodal metastases? Results of a Prospective Study. Ann Surg Oncol.
2016;23(11):3467–3474. doi:10.1245/s10434-016-5246-8
71. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node
surgery after neoadjuvant chemotherapy in patients with node-positive
breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA.
2013;310(14):1455–1461. doi:10.1001/jama.2013.278932

Hyder et al
72. Boughey JC, Ballman KV, Le-petross HT, et al. Identification and
resection of clipped node decreases the false-negative rate of sentinel
lymph node surgery in patients presenting with node-positive breast
cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy:
results from ACOSOG Z1071 (alliance). Ann Surg. 2016;263
(4):802–807. doi:10.1097/SLA.0000000000001375
73. Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary
evaluation following neoadjuvant therapy for patients with
node-positive breast cancer using selective evaluation of clipped
nodes: implementation of targeted axillary dissection. J Clin Oncol.
2016;34(10):1072–1078. doi:10.1200/JCO.2015.64.0094
74. Olivotto IA, Lesperance ML, Truong PT, et al. Intervals longer than
20 weeks from breast-conserving surgery to radiation therapy are
associated with inferior outcome for women with early-stage breast
cancer who are not receiving chemotherapy [published correction
appears in J Clin Oncol. 2009 May 10;27(14):2415]. J Clin Oncol.
2009;27(1):16–23. doi:10.1200/JCO.2008.18.1891
75. Phan C, Mindrum M, Silverman C, Paris K, Spanos W. Matchedcontrol retrospective study of the acute and late complications in
patients with collagen vascular diseases treated with radiation
therapy. Cancer J. 2003;9(6):461–466. doi:10.1097/00130404200311000-00005
76. Chen AM, Obedian E, Haffty BG. Breast-conserving therapy in the
setting of collagen vascular disease. Cancer J. 2001;7(6):480–491.
77. Holmes D, Colfry A, Czerniecki B, et al. Performance and practice
guideline for the use of neoadjuvant systemic therapy in the manage
ment of breast cancer. Ann Surg Oncol. 2015;22(10):3184–3190.
doi:10.1245/s10434-015-4753-3
78. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA,
Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the
setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86
(1):97–100. doi:10.1038/clpt.2009.68

Dovepress

Breast Cancer: Targets and Therapy

Publish your work in this journal
Breast Cancer - Targets and Therapy is an international, peer-reviewed
open access journal focusing on breast cancer research, identifi
cation of therapeutic targets and the optimal use of preventative
and integrated treatment interventions to achieve improved out
comes, enhanced survival and quality of life for the cancer patient.

The manuscript management system is completely online and includes
a very quick and fair peer-review system, which is all easy to use. Visit
http://www.dovepress.com/testimonials.php to read real quotes from
published authors.

Submit your manuscript here: https://www.dovepress.com/breast-cancer—targets-and-therapy-journal

Breast Cancer: Targets and Therapy 2021:13

submit your manuscript | www.dovepress.com

DovePress

211

